Correlation Between Exagen and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Exagen and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Exagen and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Exagen Inc and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Exagen and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Exagen with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Exagen and Mineralys Therapeutics,.

Diversification Opportunities for Exagen and Mineralys Therapeutics,

-0.59

Correlation Coefficient

Exagen  Mineralys Therapeutics,

Excellent diversification

The 3 months correlation between Exagen and Mineralys is -0.59. Overlapping area represents the amount of risk that can be diversified away by holding Exagen Inc and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Exagen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Exagen Inc are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Exagen i.e., Exagen and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Exagen and Mineralys Therapeutics,

Considering the 90-day investment horizon Exagen Inc is expected to under-perform the Mineralys Therapeutics,. In addition to that, Exagen is 2.71 times more volatile than Mineralys Therapeutics, Common. It trades about -0.15 of its total potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about -0.02 per unit of volatility. If you would invest  1,255  in Mineralys Therapeutics, Common on October 5, 2024 and sell it today you would lose (30.00) from holding Mineralys Therapeutics, Common or give up 2.39% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Exagen Inc  vs.  Mineralys Therapeutics, Common

Exagen Inc

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Exagen Inc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Exagen displayed solid returns over the last few months and may actually be approaching a breakup point.

Mineralys Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Exagen and Mineralys Therapeutics,

The main advantage of trading using opposite Exagen and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Exagen position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind Exagen Inc and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.